SCHEMBL21333151

SCHEMBL21333151

COC(=O)c1cccc(Cn2ncc(C(=O)CBr)c2C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
ABHD6 Q9BV23 1/20 0.50
MAPK10 P53779 1/20 0.48
ADORA2A P29274 2/20 0.46
ADORA1 P30542 2/20 0.46
LOXL2 Q9Y4K0 1/20 0.46
CYP4F2 P78329 2/20 0.45
CYP4A11 Q02928 2/20 0.45
CD74 P04233 1/20 0.43
MIF P14174 1/20 0.43
TRPA1 O75762 1/20 0.43
IDO1 P14902 1/20 0.42
SLC7A5 Q01650 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 2/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
GAA P10253 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21332804 0.87 KMT2A (0.56) KMT2ASMN1; SMN2ABHD6MAPK10ADORA2A
SCHEMBL21332960 0.82 KMT2A (0.44) KMT2ASMN1; SMN2ABHD6MAPK10ADORA2A
SCHEMBL31675001 0.82 KMT2A (0.44) KMT2ASMN1; SMN2ABHD6MAPK10ADORA2A
SCHEMBL21333079 0.81 SMN1; SMN2 (0.51) KMT2ASMN1; SMN2MEN1NPC1LMNA
SCHEMBL21333077 0.79 KMT2A (0.48) KMT2ASMN1; SMN2POLB
SCHEMBL21333022 0.76 ALDH1A1 (0.45) KMT2ASMN1; SMN2MAPK1MAPT
SCHEMBL21332993 0.76 ABHD6 (0.42) KMT2ASMN1; SMN2ABHD6MAPK10ADORA2A
SCHEMBL15176566 0.76 SMN1; SMN2 (0.60) KMT2ASMN1; SMN2ADORA2AADORA1NPC1
SCHEMBL1403420 0.75 ABHD6 (0.49) KMT2ASMN1; SMN2ABHD6MAPK10ADORA2A
SCHEMBL7055209 0.74 LMNA (0.69) KMT2ASMN1; SMN2ABHD6MAPK10LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3762377-B1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF UNIV CORNELL (US) 2025-08-20 EP disclosed
US-11964960-B2 Pyridinone- and pyridazinone-based compounds and uses thereof CORNELL UNIVERSITY (US) 2024-04-23 US disclosed
EP-3762377-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF Cook, Timothy, H. (US) 2021-01-13 EP disclosed
US-20200407339-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE 2020-12-31 US disclosed
WO-2019173790-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF HLA TIMOTHY (US) 2019-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200407339-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF PTGER1, LOXL1, COL1A1 KMT2A 4385/4885SMN1; SMN2 3979/4885ABHD6 2783/4885
US-11964960-B2 Pyridinone- and pyridazinone-based compounds and uses thereof PTGER1, LOXL1, COL1A1 KMT2A 4385/4885SMN1; SMN2 3979/4885ABHD6 2783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.